A 9,146-patient Flatiron Health study across 280 US cancer clinics found no significant overall-survival difference between the three CDK4/6 inhibitors, which is exactly why KOL influence, not clinical differentiation, decides prescribing share.
The largest US real-world evidence base for HR+/HER2- metastatic breast cancer runs through Flatiron Health, an electronic-health-record database spanning roughly 280 cancer clinics and 800 sites of care nationally, covering over 721,000 breast cancer patients. A 2025 analysis of 9,146 patients starting first-line CDK4/6 inhibitor therapy between February 2015 and November 2023 found no significant overall-survival difference across palbociclib, ribociclib, and abemaciclib. Every pairwise hazard ratio sat between 0.95 and 0.98, none statistically significant. That distributed, community-oncology-heavy evidence base is structurally different from the concentrated academic consortia AXLRx maps in the UK and GCC. Our KOL Universe gate (K1) has to size both ends of that spread: the academic centres setting guideline norms, and the community-oncology majority actually prescribing at volume.
That equivalence finding raises the stakes on tiering influence correctly. When three drugs perform the same on survival, the prescribing decision shifts to tolerability profile, administration convenience, and which KOL a community oncologist trusts, exactly the kind of influence our Tier Classification gate (K2) is built to score. No named individual enters the workbook without a verification tag. Every KOL identity is checked against live trial-registry, NCCN-panel, and publication data, then marked Verified, Industry benchmark, or Requires client validation. A commercial team that mistakes publication volume for prescribing influence in a market this size wastes MSL capacity at scale, which is exactly what the K1-K6 gate structure is built to prevent.
The Flatiron Health cohort — no significant survival difference across the CDK4/6 class
| Agent | US Patients (Flatiron Cohort) | Adjusted HR vs. Palbociclib | Statistical Significance |
|---|---|---|---|
| Palbociclib | 6,831 | Reference | — |
| Ribociclib | 1,279 | 0.98 | Not significant (p=0.7531) |
| Abemaciclib | 1,036 | 0.95 | Not significant (p=0.4292) |
Sources: Rugo HS et al., Comparative overall survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR+/HER2- metastatic breast cancer in the US real-world setting, ESMO Open 2025.
What this workbook answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- The Flatiron Health equivalence finding
- the shift from clinical differentiation to tolerability, convenience, and KOL guidance
- K1 KOL Universe Sizing methodology
Delivers
- K2 Tier Classification methodology across academic and community settings
- NCCN-panel and trial-leadership weighting
- K3 Scientific Influence scoring inputs
Delivers
- The three-tag verification protocol (Verified/Industry benchmark/Requires client validation)
- live trial-registry, NCCN-panel, and publication cross-checks
- why no placeholder name ships unflagged
Custom workbook delivered in 72 hours.
Commission This WorkbookWhat's inside
- Why the academic-versus-community split, not publication count, is the single variable this workbook sizes first
- Pressure-tested against the Flatiron equivalence finding before the rest of the workbook is built out
- Every US HR+/HER2- mBC KOL sized and sourced from trial-registry, NCCN-panel, and publication data
- The 280-clinic Flatiron network as the community-side sizing anchor
- Universe boundaries: academic guideline-setters versus high-volume community prescribers
- Scientific-influence scoring across NCCN panel membership, trial leadership, and guideline authorship
- What separates a Tier 1 academic KOL from a high-volume community prescriber
- Influence inputs: trial leadership, NCCN panel role, congress presentation history
- Cross-checked against independent publication and citation data
- Readiness scoring and channel recommendations per KOL
- Sequencing implications for MSL deployment across academic and community settings
- Territory-to-KOL coverage map against the Flatiron 280-clinic footprint
- Where current MSL deployment has gaps
- Multi-market reach for KOLs active in international guideline bodies (ESMO, ABC consensus)
- Implications for coordinated versus purely domestic engagement
- The open KOL-engagement questions your medical affairs team must close
- Structured for an internal alignment session before MSL deployment
Included with every brief
How AXLRx builds this workbook
Prepared by MoatRx analysts.
Every AXLRx KOL workbook is built from live trial registries, NCCN-panel documentation, and publication records, not secondary summaries. No KOL name ships without a verification tag.
US HR+/HER2- mBC KOL sources: Rugo HS et al., ESMO Open 2025 (Flatiron Health cohort), NCCN breast cancer panel documentation, and trial-registry investigator records.
- Flatiron cohort size, patient split, and hazard ratios verified against Rugo HS et al., ESMO Open 2025
- Flatiron Health database scope (280 clinics, 800 sites, 721,000+ patients) verified against the same publication
- Every KOL entry in the underlying workbook carries a three-tag verification status before delivery: Verified, Industry benchmark, or Requires client validation
Frequently asked questions
Commission this workbook
AXLRx delivers KOL mapping workbooks built for medical affairs and commercial teams engaging US HR+/HER2- mBC specialists. Custom workbook in 72 hours.
Specify your indication, geography, and institution scope.
AXLRx analyst confirms institution scope and verification standard before building.
Research-verified KOL workbook in 72 hours with optional analyst readout.